{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"contributor": "Gretchen Morgenson and Alexandra Stevenson contributed reporting.", "original": "By KATIE THOMAS", "person": [{"rank": 1, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}]}, "abstract": "Valeant Pharmaceuticals shares drop over 50 percent after company releases earnings guidance and warns it may default on some of its debt; company says it now expects 2016 revenue of $11 billion to $11.2 billion, down from previous forecast of $12.5 billion to $12.7 billion.  ", "type_of_material": "News", "word_count": "813", "lead_paragraph": "The company, which is facing inquiries over its drug-pricing policies, had previously delayed the release of its earnings. Its shares dropped sharply.", "pub_date": "2016-03-16T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Battered Valeant Stock Drops a Further 50% After Weak Guidance", "print_headline": "A Warning on Earnings by Valeant Sends Its Shares Into a Tailspin"}, "snippet": "The company, which is facing inquiries over its drug-pricing policies, had previously delayed the release of its earnings. Its shares dropped sharply.", "multimedia": [{"height": 126, "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/03/16/business/valeant-q4-financial-2016-guidance.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "N", "value": "Company Reports", "name": "subject"}], "blog": [], "_id": "56e7f4b038f0d83d7cbf5024", "source": "The New York Times"}